Active Filter(s):
Details:
The acquisition follows two years of successful partnership that brought the first-ever registered stem cell-based veterinary medicine to the European market.
Lead Product(s): Mesenchymal stem cell therapy
Therapeutic Area: Immunology Product Name: Arti-Cell
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 27, 2020